<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Elomatic</provider_name><provider_url>https://www.elomatic.com</provider_url><author_name>Matti Vehni&#xE4;inen</author_name><author_url>https://www.elomatic.com/author/mattiadmin/</author_url><title>Elomatic takes lead in FinVector&#x2019;s new pharmaceutical plant project</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="MDlpETOOh8"&gt;&lt;a href="https://www.elomatic.com/news/elomatic-takes-lead-in-finvectors-new-pharmaceutical-plant-project/"&gt;Elomatic takes lead in FinVector&#x2019;s new pharmaceutical plant project&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.elomatic.com/news/elomatic-takes-lead-in-finvectors-new-pharmaceutical-plant-project/embed/#?secret=MDlpETOOh8" width="600" height="338" title="&#x201C;Elomatic takes lead in FinVector&#x2019;s new pharmaceutical plant project&#x201D; &#x2014; Elomatic" data-secret="MDlpETOOh8" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.elomatic.com/wp-includes/js/wp-embed.min.js
&lt;/script&gt;
</html><thumbnail_url>https://www.elomatic.com/wp-content/uploads/2024/10/Havainnekuva-Finport-1500x843_web.jpg</thumbnail_url><thumbnail_width>1500</thumbnail_width><thumbnail_height>843</thumbnail_height><description>The production of bladder cancer medications is expanding in Kuopio, Finland, as pharmaceutical company FinVector launches the construction of its new GMP6 facility, aiming to improve global access to these treatments. Chosen as a key partner, Elomatic will support FinVector with comprehensive project management, serving in a central advisory role.</description></oembed>
